Dermata Therapeutics Warrant
DRMAW
DRMAW was delisted on the 17th of August, 2026.
5 hedge funds and large institutions have $17.9K invested in Dermata Therapeutics Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
2.76% less ownership
Funds ownership: 3.34% → 0.59% (-2.8%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $11.8K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$10.8K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$802 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$181 |
DRMAW Hedge Fund Activity: Q1 2023 in Review
5 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2023, worth a combined $17.9K — up 62% from $11K a quarter earlier.
Fund positioning in DRMAW was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was Armistice Capital, cutting an estimated $10.8K.
- 5 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $17.9K of Dermata Therapeutics Warrant stock for Q1 2023, up 62% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q1 2023 and 0 closed out.
- The largest Dermata Therapeutics Warrant seller in Q1 2023 was Armistice Capital, an estimated $10.8K sold.
Based on aggregated 13F filings for Q1 2023.